Chemoinformaics analysis of 9,19-Cyclolanostan-3-ol
| Molecular Weight | 428.745 | nRot | 5 |
| Heavy Atom Molecular Weight | 376.329 | nRig | 22 |
| Exact Molecular Weight | 428.402 | nRing | 5 |
| Solubility: LogS | -6.513 | nHRing | 0 |
| Solubility: LogP | 8.357 | No. of Aliphatic Rings | 5 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 5 |
| Atoms Count | 83 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 31 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 5 |
| No. of Hydrogen atom | 52 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 30 | No. of Saturated Rings | 5 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 85.5752 |
| nHD | 1 | BPOL | 52.1668 |
| QED | 0.467 |
| Synth | 5.253 |
| Natural Product Likeliness | 2.876 |
| NR-PPAR-gamma | 0.082 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.016 |
| Pgp-sub | 0 |
| HIA | 0.005 |
| CACO-2 | -4.963 |
| MDCK | 0.0000118 |
| BBB | 0.181 |
| PPB | 0.958692 |
| VDSS | 1.434 |
| FU | 0.0145501 |
| CYP1A2-inh | 0.039 |
| CYP1A2-sub | 0.175 |
| CYP2c19-inh | 0.101 |
| CYP2c19-sub | 0.949 |
| CYP2c9-inh | 0.171 |
| CYP2c9-sub | 0.253 |
| CYP2d6-inh | 0.131 |
| CYP2d6-sub | 0.188 |
| CYP3a4-inh | 0.736 |
| CYP3a4-sub | 0.549 |
| CL | 9.491 |
| T12 | 0.026 |
| hERG | 0.756 |
| Ames | 0.003 |
| ROA | 0.084 |
| SkinSen | 0.95 |
| Carcinogencity | 0.105 |
| EI | 0.413 |
| Respiratory | 0.897 |
| NR-Aromatase | 0.275 |
| Antiviral | No |
| Prediction | 0.671074 |